CompletedPhase 1NCT02097134
Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Studying Retinoblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Murali M Chintagumpala, MDChildren's Oncology Group
- Intervention
- Melphalan(drug)
- Enrollment
- 14 target
- Eligibility
- All sexes
- Timeline
- 2014 – 2023
Study locations (12)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Yale University, New Haven, Connecticut, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
- M D Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02097134 on ClinicalTrials.govOther trials for Retinoblastoma
Additional recruiting or active studies for the same condition.